78 results about "Early-stage cancer" patented technology

The subject disclosure presents systems and computer-implemented methods for providing reliable risk stratification for early-stage cancer patients by predicting a recurrence risk of the patient and to categorize the patient into a high or low risk group. A series of slides depicting serial sections of cancerous tissue are automatically analyzed by a digital pathology system, a score for the sections is calculated, and a Cox proportional hazards regression model is used to stratify the patient into a low or high risk group. The Cox proportional hazards regression model may be used to determine a whole-slide scoring algorithm based on training data comprising survival data for a plurality of patients and their respective tissue sections. The coefficients may differ based on different types of image analysis operations applied to either whole-tumor regions or specified regions within a slide.

The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye/radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and/or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.

The present invention concerns a method of prognosing the risk of early ovarian cancer relapse in a subject having ovarian cancer comprising: a) detecting the level of at least one marker selected from the group consisting of BTF4, GCS and HLA-DRbeta1; and b) comparing the level of the above at least one marker with that of a corresponding control sample, wherein the detection of a lower level of the at least one marker compared to that in the control sample is indicative that the subject is at risk of early cancer relapse. Also provided is a method of stratifying a subject suffering from ovarian cancer based on the expression levels of the disclosed markers and kits for practicing the methods of the present invention.

The invention relates to a method and a system for fusing B ultrasonic imaging and microwave imaging. By mapping pixel points of either an B ultrasonic image or a microwave image to the other image, related pixel points of the two images achieve consistency in spatial position, so that fusion of the two images is completed. Various imaging modes can be adopted for complementing each other's advantages in the process of diagnosing patients with early-stage cancers; image fusion has a potential that, with the comprehensive application of information obtained by imaging devices, the spatial position size and the geometrical shape of a diseased body as well as the spatial relationship between the diseased body and surrounding biological tissues can be accurately determined, so that diseases can be diagnosed timely and efficiently; and the method and the system can be also applied to such aspects as development of surgical planning, tracking of pathological changes, assessment of a treatment effect and the like.

The invention is called as a big-data cancer monitoring system. The invention relates to monitoring of an early-stage cancer based on personal information and blood and urine assay data in a physical examination, belongs to big data application in medical fields and is a cross technical field of big data and medical science. The invention mainly aims to provide a simple, feasible and highly accurate early-stage cancer monitoring system. At present, most early-stage cancer prediction and monitoring are related with genes and biomarkers; all the prediction and monitoring are controlled and managed by hospitals and doctors; and a user cannot monitor the early-stage cancer. Through application of the personal information and the blood and urine assay data in the physical examination of the user, the system provided by the invention predicts probability and a score for the user's suffering from the cancer, provides an analysis result report related to possibility of the early-stage cancer, and helps the user monitor the early-stage cancer.

The invention relates to a mask with a breath detection function; the mask comprises a mask body, a mouth cover, elastic bands, an air inlet filter box and a one-way ventilation valve; two ends of the elastic band are respectively connected with two sides of the mask body; the mask body is provided with the air inlet filter box; the mask also comprises an intelligent control module, an intelligent image module, a global positioning module and a display module; a second end the mouth cover is provided with a heating filtering layer; the intelligent control module is used for detecting the changes of the heating filtering layer. The mask with the breath detection function is low in cost, small in structure, simple in operation, can noninvasively and randomly and intelligently detect the breath, has pain stopping function and good pollution air protection effect, can detect breath abnormity sub-health state, can detect early stage cancer, and has pain stopping, refreshing, and global positioning functions, thus promoting large scale application.

A method for determining whether early stage cancer is present in a subject comprises detecting the expression level of GASP-1 in the subject by detecting the amount of GASP-1 peptide fragments present in a biological sample of the subject. Because cancer can be detected at an early stage, therapeutic targeting may be initiated before cancer reaches late stage (e.g., before the development of overt symptoms). A method for treating early stage cancer in a subject comprises administering to the subject an effective amount of a GASP-1 inhibitor to inhibit the progression of early stage cancer to late stage cancer. A Competitive ELISA capable of detecting GASP-1 peptide fragments at a concentration of less than 1 ng/ml was developed.

The invention discloses an early-stage cancer screening method and a kit. The method comprises a step of applying chitinase-3-like protein 1 (YKL-40) to screening of early-stage cancer. Thus, the method and kit provided by the invention can be used for early-stage cancer screening during physical examination.

This invention discloses a realization method and a device for automatically amplification of a lens of an early-stage cancer detector. The device comprises a camera, a microscope with a amplification times adjustment ring, and a amplification times adjustment mechanism controlled by a central control system. The central control system obtains the current amplification times of the microscope, compares the current amplification times with a preset amplification times and controls the amplification times adjustment mechanism according to the comparison result. The amplification times adjustment mechanism controls the amplification times adjustment ring of the microscope to rotate to a preset position. Through comparing the current amplification times with the preset amplification times and controlling the amplification times adjustment ring to rotate so as to realize the automatic adjustment for the amplification times of the lens.

The invention discloses a detection Panel and kit for pan-cancerous detection or targeted medication based on second generation sequencing and application of the detection Panel and kit. The detectionPanel comprises a target gene region used for detecting pan-cancerous mutation burden and mutation sites related to targeted medication, and an exon region related to pan-cancerous mutation sites. According to the invention, a liquid (blood) biopsy method is adopted, and a combined determination method is used for carrying out genetic change and protein biomarkers; the detection Panel not only can identify the existence of relatively early cancers, but also can locate origin organs of the cancers, has higher sensitivity, can better carry out combined detection, and provides more accurate support for treatment diagnosis of targeting drugs, chemotherapeutic drugs or immune drugs; and by designing and integrating common areas of different mutation-type information, the uniformity of the Panel is improved, the overall data volume of the Panel is reduced, and the cost is reduced.

The invention belongs to the technical field of medical treatment and relates to a multi-modal intelligent auxiliary diagnosis and treatment system formedical images. The system comprises an acquisition unit and a diagnosis and treatment information management unit; the diagnosis and treatment information management unit is provided with an analysis unit and a diagnosis and treatment unit; the acquisition unit acquires a plurality of comparative cases; image processing and category analysis are carried out on the comparative cases through a processing comprehensive unit; the comparative cases are sent to an analysis unit; after biological characteristics of the comparative cases are analyzed through an optimization unit; the analysis unit carries out AI prognosis algorithm detection on the comparative cases through an algorithm unit; the acquisition unit acquires diagnosis and treatment data and medical record information of a patient through a diagnosis and treatment instrument; an image preprocessing unit preprocesses the diagnosis and treatment data and sends the data to the diagnosis and treatment unit; a comparison unit compares detection data of the algorithm unit; and the score and the diagnosis report of a radiation prediction carrier are obtained through a detection unit. The problems of low film reading efficiency of a hospital and failure of the hospital to pre-judge early-stage cancers are solved.

The invention discloses a combined general check protein chip for early-stage cancers mainly comprising lung cancer and belongs to the technical field of a protein chip. The combined general check protein chip for the early-stage cancers mainly comprising the lung cancer, provided by the invention, comprises a chip substrate and marker antibodies distributed on the chip substrate, wherein the chip substrate is an FAST protein chip substrate having a three-dimensional nitrocellulose basic material; one or more sample application module is arranged on the FAST protein chip substrate; the following marker antibodies are fixed on the sample application module: 14-3-3 theta, LAMR-1, TSGF (Tumor Specific Growth Factor), CEA (Cancer Embryo Antigen), SCC (Squamous Cell Carcinoma), CYFRA21-1 and positive control; the following marker antibodies are also fixed: AFP (Alpha Fetal Protein), CA242, MG-Ag, CA199, TPA (Tissue Polypeptide Antigen) and EA-IgA; and the following marker antibodies are further fixed: CA125, CA153, SF (Serum Ferritin) and PSA (Prostate Specific Antigen). According to the combined general check protein chip provided by the invention, the related indexes are highly integrated; the combined general check protein chip has the advantages of excellent stability, strong specificity, long retention period, high sensitivity, excellent repeatability, convenience in operation and low cost; the labor efficiency is increased; and a cancer patient is diagnosed and treated from the general check before clinical symptoms occur.

The invention discloses a suspicious early-stage cancer lesion examination device suitable for an endoscopy. A medical endoscope (a gastroscope, an enteroscope, a bronchoscope, a cystoscope, a colposcope, a laparoscope and the like) used in medical clinical examinations becomes an important tool for disease diagnosis. Many cancers can be found through observing the morphological characteristic of a pathological changed region, however, the pathological changes of early-stage cancers without remarkable morphological characteristics are difficultly detected, a great number of medical researches show that the early-stage pathological changes of the cancers are not remarkably changed in shape, but fluorescent substances in the cancer tissue are changed along with the formation of the canceration, then, the fluorescence of a cancer tissue is caused to be greatly different from that of a normal tissue, and thus, the suspicious lesions of the early-stage cancers are identified easily through fluorescence detection and expression of a difference by using a false color image way, the pathological biopsy can also be precisely indicated, and the suspicious early-stage cancer lesion examination device plays an important role in increasing the detection rate and the accuracy rate of early-stage cancer diagnosis.

The invention discloses an early-stage cancer detection method based on a terahertz attenuated total reflection mode, a physical model of interaction between multiple interfaces of a total reflectionsurface, a sample pool bottom surface, a cell layer and a buffer solution layer and evanescent waves is established, and total reflection occurs at the sample pool bottom surface-cell layer interfacebecause the total reflection surface and the sample pool bottom surface are made of the same material. The detection of the terahertz characteristic fingerprint spectrum based on the cells has highersensitivity and accuracy than the detection based on the cell morphology.

The state of protein phosphorylation and glycosylation can be key determinants of cellular physiology such as early stage cancer, but the development of phosphoproteins and/or glycoproteins in biofluids for disease diagnosis remains elusive. Here we demonstrate, for the first time, a strategy to isolate and identify phosphoproteins/glycoproteins in extracellular vehicles (EVs) from human plasma as potential markers to differentiate disease from healthy states. We identified close to 10,000 unique phosphopeptides in EVs by isolating from small volume of plasma samples. Using label-free quantitative phosphoproteomics, we identified 144 phosphoproteins in plasma EVs that are significantly higher in patients diagnosed with breast cancer than in healthy controls. Several novel biomarkers were validated in individual patients using Paralleled Reaction Monitoring for targeted quantitation. Similarly a group of glycoproteins in plasma EVs are identified. The study demonstrated that the development of phosphoproteins and/or glycoproteins in plasma EV as disease biomarkers is highly feasible and may transform cancer screening and monitoring.

Ultraspecific, programmable nucleic acid sensors capable of detecting and preferentially amplifying target DNA molecules comprising a particular SNP or mutation are provided. In some cases, the ultraspecific programmable nucleic acid sensors are useful for detecting SNP-containing DNA molecules indicative of cancer such as cell-free DNA circulating in the blood or indicative of organ transplant rejection Also provided are methods for construction of such ultraspecific nucleic acid sensors and methods for preferential amplification of target DNA molecules containing a mutation of interest, as well as testing systems for early cancer screening and routine monitoring of circulating cancer DNA using liquid biological samples such as serum, plasma, or saliva.

The invention discloses an SERS labeled nanoprobe with a gold-hexanethiol-mesoporous silicon structure, and a preparation method and application thereof. According to the preparation method, introducing hexanethiol and mesoporous silicon into the surfaces of gold nanoparticles marked by 4-MBA to form an SERS marked nanoprobe with a gold-hexanethiol-mesoporous silicon structure, and fixing signal molecules by utilizing molecular intervals formed by hexanethiol so as to weaken thermotactic motion of the signal molecules under laser thermal induction, so that a more stable Raman signal is formed;the coated mesoporous silicon forming a structure similar to a molecular sieve, so that the influence of biomacromolecules in cells on signal molecules is avoided, and the stability and accuracy of Raman signals are further improved. The nanoprobe disclosed by the invention can be massively prepared in advance. During operation, only the nanoprobe needs to be introduced into cancer cells for co-mixed culture, and detection can be immediately carried out by washing after completion: the collection time is 1s, and then the pH value is read out from a standard curve, so that rapid quantitative detection is realized. The nanoprobe can be applied to clinical diagnosis and screening of early-stage cancers.

The invention discloses an in situ hybridization detection kit which comprises a hybridization probe and a tag. The invention also discloses an in situ hybridization detection method for the microRNA-16 closely related with the various early-stage cancer pathology evolution through the kit. The method comprises the following steps: 1, contacting RNA to be detected in a substrate with the hybridization probe on condition that the hybridization probe and a target sequence can form a stable hybridization complex; and 2, detecting the hybridization complex. According to the kit and the detection method of the invention, the microRNA-16 expression level can be detected at the RNA level, and the abnormality of the microRNA-223 expression level is earlier than the abnormality of indexes detected with the imaging medicine and the present clinical biochemistry, so real early-stage canceration RNA level screening can be realized. The detection method which has the advantages of simplicity, convenience and low cost is convenient for the popularization and the application in county and district hospitals.

The invention discloses receptor-modified and receptor-free titanium dioxide nano metal film Raman chips and a manufacturing method. Each chip is composed of a surface enhanced Raman scattering (SERS) film and a carrier thereof, the carriers comprise the capillary type carrier, the small box type carrier and the microfluidic channel type carrier, the SERS-films comprise the receptor-modified SERS-film and the receptor-free SERS-film, and six types of the Raman chips are obtained. Control standards are set in the manufacturing method, and the controllable SERS-film manufacturing method comprises the steps that 1, a titanium dioxide film is pulled through a sol-gel method, and scattered particles are crystallized; 2, a second-layer nano silver foil/silver particle SERS-film grows through photocatalysis; 3, the second-layer SERS-film is modified with specifically coordinated and combined receptor molecules through hydrogen bonding force or immune bonding force according to the needs of detected object donor molecules, and then a third-layer SERS-film is formed. The Raman chips can be applied to environmental pollution treatment and detection, hard drug and warfare agent detection, pesticide residue detection, harmful food additive screening, large-scale early-stage cancer Raman screening and the like.